Company Profile
Ibaraki, Japan
AnGes provides the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease. Its portfolio also includes NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain, and DNA vaccines for the treatment of hypertension
Tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. Incorporated in 1999, the company is headquartered in Ibaraki, Japan.